CARBOPLATIN

Platinum compound anticancer

Dosage Forms

▼

Solution for infusion

10 mg/ml

Uses

▼
  • Ovarian cancer
  • Small cell lung cancer

Dose and Duration

▼
Dose depends on renal function
In previously untreated adults with normal renal function, usual dose is 400 mg/m2, given as a single IV infusion over 15‒60 minutes.

➡️ Do not repeat therapy until at least 4 weeks after previous dose

Contraindications

▼
  • Severe myelosuppression
  • Severe renal impairment
  • Patients with bleeding tumours
  • Patients with bleeding tumours

Side Effects

▼
  • Infections and infestations
  • Blood disorders and haemorrhage
  • Nausea, vomiting, abdominal pain
  • Kidney damage
  • Liver damage
  • Electrolyte disturbances
  • Hypersensitivity
  • Visual disturbance
  • Ototoxicity
  • Cardiovascular disorder
  • Cardiovascular disorder
  • Respiratory disorder
  • Musculoskeletal disorder
  • Urogenital disorder
  • Asthenia

Interactions

▼
  • Yellow fever vaccine (risk of fatal generalised disease)
  • Live vaccines (risk of systemic disease)
  • Aminoglycosides, polymixins, vancomycin (increased risk of ototoxicity and nephrotoxicity)
  • Clozapine (increased risk of agranulocytosis)

Pregnancy

▼
  • Do not use

Breastfeeding

▼
  • Discontinue breastfeeding

Storage

▼
  • Store between 2‒8°C

⚠️ Caution

▼
  • Monitor complete blood count before, during and after therapy
  • Reduce dose by 20‒25% in patients with previous myelosuppressive therapy
  • Consider dose reduction or scheduling changes when used in combination with other myelosuppressive medicines to minimise side effect
  • Do not use needles or giving sets made of aluminium parts as it forms precipitates with carboplatin
  • Anticancer medicines should only be handled by health workers trained and experienced in cytotoxic medicines